Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagement Article

sustainable development goals

publication date

  • September 22, 2024

webpage

published in

keywords

  • Alzheimer's disease
  • amyloid targeting therapies
  • anti-amyloid therapies
  • benefit
  • clinical meaningfulness
  • patient
  • patient-care dyad
  • risk
  • treatment